
BiBB Receives Notice of Allowance for Additional EndoDrill Patent in China

The cancer diagnostics company BiBB Instruments AB ("BiBB" or "the Company"), which develops EndoDrill® – the world's first market-cleared powered biopsy instrument for endoscopy – announces that the Company has received a Notice of Allowance from the China National Intellectual Property Administration (CNIPA). This means that CNIPA intends to approve a patent application for EndoDrill® in the third patent family in China. Certain formalities will now follow before final approval, after which the patent will be valid until 2041. This means that the EndoDrill® technology will be protected by two granted patents in China.

BiBB has received a Notice of Allowance from CNIPA regarding patent application 2021800378367 from patent family 3 in China. The patent provides the EndoDrill® product line with protection for the instrument and its drive system in the Chinese market. The Company has three international patent applications for EndoDrill® that have entered national/regional phase, with patents already granted in Europe, Japan, India, and China. Remaining patent applications will continue to be pursued to achieve global protection for the market's first powered endoscopic biopsy instrument.

"The approval of an additional patent in China is strategically important and strengthens our global IP portfolio. It enhances the prospects for a successful future global launch in partnership with a distribution partner," says Fredrik Lindblad, CEO of BiBB.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:

Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

This disclosure contains information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 CET on April 7, 2025.

About BiBB

The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill®, a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill® instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill® GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. Thus EndoDrill® is the first cleared powered endoscopic biopsy system in both the US and Europe. The EndoDrill® system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.